SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

12 Months Ended

Dec. 31, 2025

Accounting Policies [Abstract]

SCHEDULE OF INVENTORIES

Inventories are as follows as of December 31,

	2025			2024
Raw materials	$	20,575		$	21,122
Work in process		1,003			892
Finished goods		970			1,070
Reserves		(1,853	)		(1,446	)
Total	$	20,695		$	21,638

SCHEDULE OF ESTIMATED USEFUL LIVES

	(in years)
Building		39
Leasehold improvements		3 - 15
Manufacturing equipment		3 - 7
Office and other equipment		3 - 7

SCHEDULE OF PROPERTY AND EQUIPMENT

Property and equipment are as follows as of December 31,

	2025			2024
Land	$	-		$	148
Building and leasehold improvements		3,927			6,027
Manufacturing equipment		19,444			20,807
Office and other equipment		6,680			6,523
Accumulated depreciation and amortization		(24,848	)		(27,273	)
Total property and equipment, net	$	5,203		$	6,232

SCHEDULE OF CONTRACT ASSETS

Contract assets, recorded as such in the consolidated balance sheets, consist of unbilled amounts related to net sales recognized over time. Changes in the contract assets balance during the years ended December 31, 2025 and 2024 were as follows:

Balance outstanding as of December 31, 2023	$	14,481
Increase (decrease) attributed to:
Amounts transferred over time to contract assets		97,724
Reversal of allowance for current expected credit losses		4
Amounts invoiced during the period		(98,417	)
Balance outstanding as of December 31, 2024	$	13,792
Increase (decrease) attributed to:
Amounts transferred over time to contract assets		89,530
Allowance for current expected credit losses		(1	)
Amounts invoiced during the period		(88,137	)
Balance outstanding as of December 31, 2025	$	15,184

SCHEDULE OF NET SALES BY MARKET

The following tables summarize our net sales by market for the years ended December 31, 2025 and 2024:

	Year Ended December 31, 2025
	Product/ Service Transferred Over Time		Product Transferred at Point in Time		Noncash Consideration		Total Net Sales by Market
Medical Device	$	22,361	$	7,387	$	2,182	$	31,930
Medical Imaging		31,908		7,996		95		39,999
Industrial		22,152		8,153		635		30,940
Aerospace and Defense		13,109		2,124		263		15,496
Total net sales	$	89,530	$	25,660	$	3,175	$	118,365

	Year Ended December 31, 2024
	Product/ Service Transferred Over Time		Product Transferred at Point in Time		Noncash Consideration		Total Net Sales by Market
Medical Device	$	24,085	$	7,487	$	3,064	$	34,636
Medical Imaging		29,362		8,104		26		37,492
Industrial		25,652		8,620		1,245		35,517
Aerospace and Defense		18,625		1,658		205		20,488
Total net sales	$	97,724	$	25,869	$	4,540	$	128,133

SCHEDULE OF BASIC AND DILUTED WEIGHTED AVERAGE SHARES OUTSTANDING

	Years Ended December 31,
	2025		2024
Basic weighted average shares outstanding		2,776,680		2,755,041
Dilutive effect of outstanding stock options and non-vested restricted stock units1		-		-
Diluted weighted average shares outstanding		2,776,680		2,755,041

¹ The following items were excluded from the computation of diluted weighted-average shares outstanding as their inclusion would be anti-dilutive:

a.	For the year ended December 31, 2025, restricted stock units and stock options totaling 533,846.
b.	For the year ended December 31, 2024, restricted stock units and stock options totaling 477,541.